Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross SD Rezdiffra Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.05.40

    Rezdiffra (resmetirom) Coverage

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.05.40 alerts

    Get alerted when Policy 05.05.40 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and coverage criteria for Rezdiffra (resmetirom) in adults with noncirrhotic MASH and moderate to advanced F2-F3 liver fibrosis.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyRezdiffra (resmetirom) Coverage
    Policy CodePolicy 05.05.40
    Change TypeNo material change
    Effective DateMarch 17, 2026
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization requests with the required clinical and lifestyle documentation and satisfy all applicable approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsAuthorization period
    F2-F3Required fibrosis stage
    3+Managed risk factors required
    30/30 daysQuantity limit
    18+

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Minimum age
    Not medically necessaryWhen criteria are unmet

    Coverage Criteria

    Initial Therapy

    Covered for initial therapy when ALL of the following are met:

    • Age: Member is 18 years of age or older.>= 18 years
    • MASH and fibrosis confirmation

      • Accepted confirmation method: Member has a diagnosis of MASH with moderate to advanced liver fibrosis consistent with stages F2 to F3, confirmed by liver biopsy, FAST, MAST, or MEFIB.F2 to F3 fibrosis; one accepted confirmation method
    • Metabolic risk factors: At least three of the following metabolic risk factors are present and managed according to standard of care: obesity, hypertriglyceridemia, reduced HDL cholesterol, hypertension, or elevated fasting plasma glucose indicative of pre-diabetes or diabetes.>= 3 risk factors
    • Disease status, alcohol use, and lifestyle modifications

      • Member does not have evidence of cirrhosis, hepatic decompensation, or hepatocellular carcinoma (HCC).
      • Alcohol consumption is no more than 20 g/day in females or 30 g/day in males.<= 20 g/day in females; <= 30 g/day in males
      • The requested drug will be used in conjunction with healthy lifestyle modifications, such as dietary or caloric restriction, exercise, behavioral support, or a community-based program.

    Continuation Therapy

    Covered for continuation therapy when ALL of the following are met:

    • Member has achieved or maintained a positive clinical response to the requested drug.Positive clinical response from baseline

      Examples include improvement in liver function, such as reduction in ALT, or reduction of liver fat content measured by MRI-PDFF or FibroScan CAP.

    Use of Rezdiffra (resmetirom) should be avoided in patients with decompensated cirrhosis.

    For initial approval, the member must have no evidence of cirrhosis, hepatic decompensation, or hepatocellular carcinoma (HCC).

    Rezdiffra (resmetirom) is considered not medically necessary when the member does not meet the criteria set forth in this policy.

    Coding and Coverage Parameters

    Procedures and Billing Codesmixed
    N/ANo specific CPT, HCPCS Level II, revenue, or ICD diagnostic codes listed.
    Age
    Minimum age18 years or older
    Applies toInitial approval
    Treatment populationAdults with metabolic dysfunction-associated steatohepatitis (MASH)
    Liver fibrosis
    Required fibrosisModerate to advanced liver fibrosis consistent with stages F2 to F3
    ConditionMetabolic dysfunction-associated steatohepatitis (MASH)
    ConfirmationMust be confirmed by liver biopsy, FAST, MAST, or MEFIB

    Provider Requirements and Denial Risks

    Prior Authorization

    Prior Authorization and Documentation Required

    Prior authorization is required before initiating or continuing Rezdiffra (resmetirom). Submit clinical documentation supporting MASH, evidence of required fibrosis and metabolic-risk criteria, healthy lifestyle changes, and— for reauthorization—evidence of positive clinical response.

    • Initial authorization is granted for 12 months when all applicable criteria are met.
    • Continuation authorization is granted for 12 months when positive clinical response is achieved or maintained.
    Documentation Required

    Specialist Prescriber or Consultation Required

    The medication must be prescribed by or used in consultation with a qualified specialist.

    • Gastroenterologist
    • Hepatologist

    Clinical Background

    Rezdiffra (resmetirom) is indicated in conjunction with diet and exercise for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis consistent with stages F2 to F3.

    Definitions

    MASH
    Full termMetabolic dysfunction-associated steatohepatitis
    Former terminologyFormerly known as nonalcoholic steatohepatitis (NASH)
    Fibrosis contextModerate to advanced liver fibrosis consistent with stages F2 to F3
    FAST
    AbbreviationFAST
    MeaningFibroScan-aspartate aminotransferase
    Use in policyAn accepted method for confirming MASH with F2 to F3 fibrosis

    Initial Therapy Authorization

    MASH Initial Therapy

    Authorization of 12 months may be granted when ALL of the following criteria are met:

    MASH initial therapy

    • Member is 18 years of age or older.>= 18 years
    • Member has a diagnosis of MASH with moderate to advanced liver fibrosis consistent with stages F2 to F3, confirmed by liver biopsy, FAST, MAST, or MEFIB.F2 to F3 fibrosis; confirmed by one accepted method
    • Metabolic risk factors: At least three of the following metabolic risk factors are present and managed according to standard of care: obesity, hypertriglyceridemia, reduced HDL cholesterol, hypertension, or elevated fasting plasma glucose indicative of pre-diabetes or diabetes.

    Continuation Therapy Authorization

    MASH Continuation Therapy

    Authorization of 12 months may be granted for reauthorization when ALL of the following are met:

    MASH continuation therapy

    • Member has achieved or maintained a positive clinical response to the requested drug, such as improvement in liver function including reduction in ALT or reduced liver fat content measured by MRI-PDFF or FibroScan CAP.Positive clinical response from baseline

    Quantity and Dosing Limits

    Rezdiffra quantity limit
    60 mg tablets30 tablets per 30 days
    80 mg tablets30 tablets per 30 days
    100 mg tablets30 tablets per 30 days
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyRezdiffra (resmetirom) Coverage
    Policy CodePolicy 05.05.40
    Change TypeNo material change
    Effective DateMarch 17, 2026
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization requests with the required clinical and lifestyle documentation and satisfy all applicable approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Coverage ParametersProvider Requirements and Denial RisksClinical BackgroundDefinitionsInitial Therapy AuthorizationContinuation Therapy AuthorizationQuantity and Dosing Limits
    Metabolic risk factors
    Minimum numberThree or more metabolic risk factors
    Management requirementRisk factors must be managed according to standard of care
    ExamplesObesity, hypertriglyceridemia, reduced HDL cholesterol, hypertension, or elevated fasting plasma glucose indicative of pre-diabetes or diabetes
    Alcohol consumption, females
    Maximum consumption20 g/day
    PopulationFemales
    Approval criterionAlcohol consumption must not exceed the specified limit
    Alcohol consumption, males
    Maximum consumption30 g/day
    PopulationMales
    Approval criterionAlcohol consumption must not exceed the specified limit
    Standard quantity limit
    Standard limit30 tablets
    DurationPer 30 days
    Applies toRezdiffra 60 mg, 80 mg, and 100 mg tablets
    Body-weight dosing threshold
    Below 100 kg80 mg orally once daily; 60 mg once daily when used with a moderate CYP2C8 inhibitor such as clopidogrel
    At least 100 kg100 mg orally once daily
    Dosing basisActual body weight
  1. Cardiometabolic specialist
  2. Documentation Required

    Document the MASH Diagnosis

    Submit chart notes or medical records documenting clinical findings that support a diagnosis of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as noncirrhotic nonalcoholic steatohepatitis (NASH).

    • Documentation must support MASH with moderate to advanced liver fibrosis consistent with stages F2 to F3.
    • Fibrosis must be confirmed by liver biopsy, FAST, MAST, or MEFIB.
    Documentation Required

    Document Lifestyle Modification

    Document that the member is engaging in healthy lifestyle modifications in conjunction with Rezdiffra therapy.

    • Heart-healthy diet or caloric restriction
    • Exercise regimen
    • Behavioral support or participation in a community-based program
    Documentation Required

    Continuation Response Documentation

    For reauthorization, submit medical records demonstrating that the member has achieved or maintained a positive clinical response to Rezdiffra from baseline.

    • Chart notes describing clinical response
    • Laboratory evidence such as reduced alanine aminotransferase (ALT)
    • Imaging evidence such as reduced liver fat content by MRI-PDFF or FibroScan controlled attenuation parameter (CAP)
    Denial Risk

    Excluded Liver Disease or Unmet Criteria

    Coverage is denied or the drug is not medically necessary when an excluded liver condition is present or when the member does not satisfy the policy criteria. Rezdiffra should be avoided in patients with decompensated cirrhosis.

    • No evidence of cirrhosis may be present.
    • No hepatic decompensation may be present; avoid use in decompensated cirrhosis.
    • No hepatocellular carcinoma (HCC) may be present.
    • Requests that do not meet all applicable policy criteria are considered not medically necessary.
    Denial Risk

    Initial Approval Requirements Not Met

    Initial approval is denied when any required eligibility or clinical criterion is absent.

    • Member is younger than 18 years.
    • MASH with moderate to advanced F2-F3 fibrosis is not documented by an accepted method: liver biopsy, FAST, MAST, or MEFIB.
    • Fewer than three metabolic risk factors are present or the risk factors are not managed according to standard of care.
    • Alcohol consumption exceeds 20 g/day for females or 30 g/day for males.
    • The drug is not used with healthy lifestyle modifications.
    • Cirrhosis, hepatic decompensation, or HCC is present.
    Denial Risk

    No Positive Clinical Response

    Continuation or reauthorization is denied when the member has not achieved or maintained a positive clinical response to Rezdiffra.

    • No documented improvement in liver function, such as reduced ALT.
    • No documented reduction in liver fat content by MRI-PDFF or FibroScan CAP.
    • Required chart notes, laboratory tests, or other medical records are absent.
    Denial Risk

    Required Specialist Involvement Absent

    A request is denied when Rezdiffra is not prescribed by, or used in consultation with, a gastroenterologist, hepatologist, or cardiometabolic specialist.

    • Document the qualified specialist prescriber or consultation in the medical record.
    MAST
    AbbreviationMAST
    DefinitionA score derived from magnetic resonance imaging-proton density fat fraction, magnetic resonance elastography, and AST
    Use in policyAn accepted method for confirming MASH with F2 to F3 fibrosis
    MEFIB
    AbbreviationMEFIB
    DefinitionMagnetic resonance elastography combined with the fibrosis-4 index (FIB-4)
    Use in policyAn accepted method for confirming MASH with F2 to F3 fibrosis
    >= 3 risk factors
  3. Disease status, alcohol use, and lifestyle modifications

    • Member does not have evidence of cirrhosis, hepatic decompensation, or hepatocellular carcinoma (HCC).
    • Alcohol consumption is no more than 20 g/day in females or 30 g/day in males.<= 20 g/day in females; <= 30 g/day in males
    • The requested drug will be used in conjunction with healthy lifestyle modifications, such as dietary or caloric restriction, exercise, behavioral support, or a community-based program.